Plasma phenylethylamine in schizophrenic patients

Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biological psychiatry (1969) 1991-07, Vol.30 (2), p.145-150
Hauptverfasser: O'Reilly, R., Davis, B.A., Durden, D.A., Thorpe, L., Machnee, H., Boulton, A.A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 150
container_issue 2
container_start_page 145
container_title Biological psychiatry (1969)
container_volume 30
creator O'Reilly, R.
Davis, B.A.
Durden, D.A.
Thorpe, L.
Machnee, H.
Boulton, A.A.
description Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.
doi_str_mv 10.1016/0006-3223(91)90168-L
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72112168</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000632239190168L</els_id><sourcerecordid>72112168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo67r6DxR6ENFDNR9t0lwEWfyCBT3oOYzplEb6ZdIV1l9v1l305ilM5nmHmYeQY0YvGWXyilIqU8G5ONfsQsefIl3skCkrlEh5Rvkumf4i--QghPdYKs7ZhEyYZpxROSXsuYHQQjLU2K0aHOtVA63rMHFdEmztvvqh9tg5mwwwOuzGcEj2KmgCHm3fGXm9u32ZP6SLp_vH-c0itaKQYyo1cmsrqQC1hjIDbqnIIWdKUM0Fcqm04rKsNFOyoApkIWgGIqdWCKwyMSNnm7mD7z-WGEbTumCxaaDDfhmM4izeEFMzkm1A6_sQPFZm8K4FvzKMmrUps9Zg1hqMZubHlFnE2Ml2_vKtxfIvtFET-6fbPgQLTeWhsy78YnmudUZFxK43GEYXnw69CTZ6slg6j3Y0Ze_-3-MbZpiC5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72112168</pqid></control><display><type>article</type><title>Plasma phenylethylamine in schizophrenic patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>O'Reilly, R. ; Davis, B.A. ; Durden, D.A. ; Thorpe, L. ; Machnee, H. ; Boulton, A.A.</creator><creatorcontrib>O'Reilly, R. ; Davis, B.A. ; Durden, D.A. ; Thorpe, L. ; Machnee, H. ; Boulton, A.A.</creatorcontrib><description>Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.</description><identifier>ISSN: 0006-3223</identifier><identifier>EISSN: 1873-2402</identifier><identifier>DOI: 10.1016/0006-3223(91)90168-L</identifier><identifier>PMID: 1912106</identifier><identifier>CODEN: BIPCBF</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Adult and adolescent clinical studies ; Age Factors ; Biological and medical sciences ; Female ; Gas Chromatography-Mass Spectrometry ; Humans ; Male ; Medical sciences ; Middle Aged ; Phenethylamines - blood ; Psychiatric Status Rating Scales ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Schizophrenia - blood ; Schizophrenia - diagnosis ; Schizophrenic Psychology ; Sex Factors</subject><ispartof>Biological psychiatry (1969), 1991-07, Vol.30 (2), p.145-150</ispartof><rights>1991</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</citedby><cites>FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0006-3223(91)90168-L$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5599403$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1912106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O'Reilly, R.</creatorcontrib><creatorcontrib>Davis, B.A.</creatorcontrib><creatorcontrib>Durden, D.A.</creatorcontrib><creatorcontrib>Thorpe, L.</creatorcontrib><creatorcontrib>Machnee, H.</creatorcontrib><creatorcontrib>Boulton, A.A.</creatorcontrib><title>Plasma phenylethylamine in schizophrenic patients</title><title>Biological psychiatry (1969)</title><addtitle>Biol Psychiatry</addtitle><description>Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Age Factors</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Phenethylamines - blood</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenic Psychology</subject><subject>Sex Factors</subject><issn>0006-3223</issn><issn>1873-2402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo67r6DxR6ENFDNR9t0lwEWfyCBT3oOYzplEb6ZdIV1l9v1l305ilM5nmHmYeQY0YvGWXyilIqU8G5ONfsQsefIl3skCkrlEh5Rvkumf4i--QghPdYKs7ZhEyYZpxROSXsuYHQQjLU2K0aHOtVA63rMHFdEmztvvqh9tg5mwwwOuzGcEj2KmgCHm3fGXm9u32ZP6SLp_vH-c0itaKQYyo1cmsrqQC1hjIDbqnIIWdKUM0Fcqm04rKsNFOyoApkIWgGIqdWCKwyMSNnm7mD7z-WGEbTumCxaaDDfhmM4izeEFMzkm1A6_sQPFZm8K4FvzKMmrUps9Zg1hqMZubHlFnE2Ml2_vKtxfIvtFET-6fbPgQLTeWhsy78YnmudUZFxK43GEYXnw69CTZ6slg6j3Y0Ze_-3-MbZpiC5g</recordid><startdate>19910715</startdate><enddate>19910715</enddate><creator>O'Reilly, R.</creator><creator>Davis, B.A.</creator><creator>Durden, D.A.</creator><creator>Thorpe, L.</creator><creator>Machnee, H.</creator><creator>Boulton, A.A.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19910715</creationdate><title>Plasma phenylethylamine in schizophrenic patients</title><author>O'Reilly, R. ; Davis, B.A. ; Durden, D.A. ; Thorpe, L. ; Machnee, H. ; Boulton, A.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-69e2ccf67ae99ad4a2c035a51730923e2679726df9176807a68304a350c33ef43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Age Factors</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Phenethylamines - blood</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenic Psychology</topic><topic>Sex Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Reilly, R.</creatorcontrib><creatorcontrib>Davis, B.A.</creatorcontrib><creatorcontrib>Durden, D.A.</creatorcontrib><creatorcontrib>Thorpe, L.</creatorcontrib><creatorcontrib>Machnee, H.</creatorcontrib><creatorcontrib>Boulton, A.A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biological psychiatry (1969)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Reilly, R.</au><au>Davis, B.A.</au><au>Durden, D.A.</au><au>Thorpe, L.</au><au>Machnee, H.</au><au>Boulton, A.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma phenylethylamine in schizophrenic patients</atitle><jtitle>Biological psychiatry (1969)</jtitle><addtitle>Biol Psychiatry</addtitle><date>1991-07-15</date><risdate>1991</risdate><volume>30</volume><issue>2</issue><spage>145</spage><epage>150</epage><pages>145-150</pages><issn>0006-3223</issn><eissn>1873-2402</eissn><coden>BIPCBF</coden><abstract>Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>1912106</pmid><doi>10.1016/0006-3223(91)90168-L</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-3223
ispartof Biological psychiatry (1969), 1991-07, Vol.30 (2), p.145-150
issn 0006-3223
1873-2402
language eng
recordid cdi_proquest_miscellaneous_72112168
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adult
Adult and adolescent clinical studies
Age Factors
Biological and medical sciences
Female
Gas Chromatography-Mass Spectrometry
Humans
Male
Medical sciences
Middle Aged
Phenethylamines - blood
Psychiatric Status Rating Scales
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Schizophrenia - blood
Schizophrenia - diagnosis
Schizophrenic Psychology
Sex Factors
title Plasma phenylethylamine in schizophrenic patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A17%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20phenylethylamine%20in%20schizophrenic%20patients&rft.jtitle=Biological%20psychiatry%20(1969)&rft.au=O'Reilly,%20R.&rft.date=1991-07-15&rft.volume=30&rft.issue=2&rft.spage=145&rft.epage=150&rft.pages=145-150&rft.issn=0006-3223&rft.eissn=1873-2402&rft.coden=BIPCBF&rft_id=info:doi/10.1016/0006-3223(91)90168-L&rft_dat=%3Cproquest_cross%3E72112168%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72112168&rft_id=info:pmid/1912106&rft_els_id=000632239190168L&rfr_iscdi=true